| Project/Area Number |
06671291
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Saga Medical School |
|---|
Principal Investigator |
KATANO Mithuo Saga Medical School, Lecturer, 医学部, 講師 (10145203)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KUBOTA Eiro Saga Medical School, Lecturer, 医学部, 講師 (50170030)
MORISAKI Takashi Kyushu Univ.School of Medicine, 医学部, 医員
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Project Status |
Completed (Fiscal Year 1995)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1995: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1994: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | Interleukin-4(IL-4) / gastric carcinoma / IL-4 receptor / Gene transfection |
|---|
| Research Abstract |
Based on the previous in vitro study which demonstrated the growth inhibitory effect of human interleukin-4 on the gastric and colonic carcinoma cell lines, in this stuby, we aimd the preclinical evaluation of IL-4 as anti-cancer agents against human gastro-intestinal tract cancers. In vivo study failed in demonstrating the inhibition of IL-4(up to 200 ug for each mouse)on the growth of gastric carcinoma cells transplanted into nude mice. However, because low dose IL-4 combined with TNF-alpha or IFN-gamma effectively inhibited the growth of the carcinoma cells in vitro, in vivo cytokine combination study needs to be tested. Although IL-4 gene transfection into gastric carcinoma cells was repeatedly carried out, we could not detect IL-4 release from those cells by ELISA assay. Additional study showed that IL-4 was detectable in the gene transfected melanoma cell line M101 ranged from 2,500 pg/106 cells/24 hr, and was undetectable 2 weeks after the transfection. These results indicated the differential activity of IL-4 production between carcinoma cells tested. However, the IL-4 transfected melanoma cells expressed more Class-1 and 2, andICAM-1 than the control, suggesting that the IL-4 gene transfected cells can be tumor vaccines. IL-4 gene transfection study using gastro-intestinal tract carcinoma cells needs to be continued and established. Recently dendritic cells have been demonstrated to be the most potent antigen-presenting cells and IL-4 and GM-CSF have been shown to be the most important for induction and proliferation of those cells. We are plannning to use IL-4 as invivo stimulator of tumor antigen presenting dendritic cells for immunotherapy.
|
